Masimo Corporation announced that Germans Trias i Pujol, is launching a breakthrough telehealth and remote patient management initiative using Masimo technology. The SESHAT project is focused on using advanced wearable technologies and wireless connectivity to allow remote clinicians to keep track of patients? physiological data in near real time wherever they are, whether the patient is in another part of the hospital or at home.

The project, which began in the fourth quarter of 2023 and is slated to last at least three years, includes the implementation of up to 1,000 Masimo W1® medical watches, 100 Radius VSM? Wearable Continuous Vital Signs Monitors, 10 Patient SafetyNet? Systems, and a host of additional Masimo Hospital Automation?

products. The SESHAT project arose from needs identified during the COVID pandemic and centers on the remote monitoring of patients with complex care requirements. The project's goal is to obtain real-time physiological data from patients and have that data help clinicians improve health outcomes.

By facilitating better tracking of each patient?s physiological changes, and combining such changes with other available health data, SESHAT project clinicians hope to design and validate better prospective indicators of clinical progress and therapeutic adherence. Their goal is ultimately to help institutions transition from a reactive care model, in which healthcare teams treat symptomatic diseases, to a more proactive model in which teams receive information that enables them to anticipate complications or select more suitable medications to ensure a better therapeutic response, based on each patient's profile. The Germans Trias i Pujol University Hospital of Badalona belongs to the Catalan Health Institute.

It is a high-tech center that provides health services to a population of 800,000 inhabitants in the North Metropolitan area of Barcelona. Since its foundation, the hospital has been a pioneer in the development and care in various areas of excellence, such as infectious, cardiovascular, inflammatory, oncological, and respiratory diseases, among others. It encompasses a powerful biomedical research campus with 12 internationally renowned institutions, employing over 6,000 professionals and researchers in the field of health.

Clinical innovation?transforming clinical problems into opportunities for improving outcomes?is one of the institution's strategic pillars. Halo is not FDA cleared and is not available in the U.S.